Collaborations & Alliances
Related Searches:
Filter by:
December 11, 2007
Bristol-Myers Squibb and Gilead Sciences have formed an agreement to commercialize Atripla in Europe for the treatment of virologically suppressed adults with HIV-1 infection. If approved in the EU, Atripla would represent that region's the first and…
Read More »
December 10, 2007
GlaxoSmithKline and OncoMed Pharmaceuticals have formed a strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells. These cells are believed to play a key role in the establishment, metastasis and rec…
Read More »
December 6, 2007
Urigen Pharmaceuticals has established a partnerships with Hyaluron Contract Manufacturing (HCM) to develop URG101, Urigen's proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).
"Urigen's de…
Read More »
December 5, 2007
Pfizer and Adolor Corp. have signed an exclusive collaboration to develop and commercialize novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to…
Read More »
December 5, 2007
Avid Bioservices has signed a manufacturing supply and technology transfer agreement with Arius Research. The agreement covers Arius' lead cancer stem cell antibody, which targets a novel epitope of CD44 found in breast, colon and prostate cancers. A…
Read More »
December 3, 2007
Novartis and MorphoSys AG have formed a comprehensive, 10-year, $600 million strategic alliance for the discovery and development of biopharmaceuticals. The deal is aimed at establishing a pipeline of innovative drugs, and establishes Novartis as Mor…
Read More »
November 30, 2007
ImmunoVaccine Technologies Inc. (IVT) has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax. The manufacturing development was performed by Dalton Pharma Services.
VacciMax is a vaccine-enhancement platform compri…
Read More »
November 29, 2007
Regeneron Pharmaceuticals and Sanofi-Aventis have entered a new collaboration, which will include a greater SA stake in the biopharma. The companies will work to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regene…
Read More »
November 28, 2007
DynPort Vaccine Co. and Baxter International have received a $201.2 million contract modification from the U.S. Department of Health and Human Services (HHS) for the development of Baxter's cell-cultured seasonal and pandemic influenza candidate vacc…
Read More »
November 27, 2007
Pharmacopeia has identified a pair of new lead compounds for advancement in its alliance with GlaxoSmithKline. The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disea…
Read More »
November 27, 2007
Genzyme and Fovea Pharmaceuticals SA have entered into a collaborative research pact centered on Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dyst…
Read More »
November 26, 2007
Santen Pharmaceutical Co., Ltd., of Osaka, Japan has begun Phase I/IIa trials of DE-102, its steroidal treatment for macular edema, employing Oakwood Laboratories' Chroniject™ sustained release delivery technology. The product's microsphere for…
Read More »
November 20, 2007
Biogen Idec and Neurimmune Therapeutics AG entered an agreement for the worldwide development and commercialization of fully human antibodies for the treatment of Alzheimer’s disease (AD). The alliance will focus on the development of antibodi…
Read More »
November 13, 2007
Pfizer and Nektar Therapeutics have reached an agreement settling their contractual issues regarding Exubera and Nektar's new inhaled insulin product, which is currently in Phase I. Nektar will receive a one-time payment of $135 million from Pfizer t…
Read More »
November 12, 2007
Synairgen, a company developing novel therapies for asthma and COPD, has selected Alpha Biologics to help with the advancement of its growth factor drug development program. Alpha will develop a scaleable manufacturing process for Synairgen's optimiz…
Read More »
